deltatrials
Completed PHASE1 NCT01967758

Phase I Study of Safety and Immunogenicity of ADU-623

Phase I Study of Safety and Immunogenicity of ADU-623, a Live-attenuated Listeria Monocytogenes Strain (ΔactA/ΔinlB) Expressing the EGFRvIII-NY-ESO-1 Vaccine, in Patients With Treated and Recurrent WHO Grade III/IV Astrocytomas

Sponsor: Aduro Biotech, Inc.

Conditions Anaplastic Astrocytoma Astrocytic Tumors Brain Tumor Glioblastoma Multiforme
Interventions Antibiotics Cohort 1 Cohort 2 Cohort 3
Updated 8 times since 2017 Last updated: Aug 15, 2018 Started: Jan 8, 2014 Primary completion: Jun 18, 2018 Completion: Aug 15, 2018

A PHASE1 clinical study on Anaplastic Astrocytoma and Astrocytic Tumors, this trial is completed. The trial is conducted by Aduro Biotech, Inc. and has accumulated 8 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

8 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Sep 2018 — Jan 2021 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  5. Jun 2018 — Sep 2018 [monthly]

    Active Not Recruiting PHASE1

▶ Show 3 earlier versions

  1. Oct 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  2. Feb 2017 — Oct 2017 [monthly]

    Recruiting PHASE1

  3. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1

    First recorded

Jan 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Aduro Biotech, Inc.
  • Providence Health & Services
Data source: Providence Health & Services

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Portland, United States